Degarelix Accord · 4.3 Contraindications · 1

HOS-100441 · has-adverse-reaction-information · PDF-Seite 5

Summary of the safety profile The most commonly observed adverse reactions during degarelix therapy in the confirmatory phase III study (N=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. Transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively). The injection site adverse reactions reported were mainly pain and erythema, reported in 28% and 17% of patients, respectively, less frequently reported were swelling (6%), induration (4%) and nodule (3%). These events occurred primarily with the starting dose whereas during maintenance therapy with the 80 mg dose, the incidence of these events pr 100 injections was: 3 for pain and <1 for erythema, swelling, nodule and induration. The reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (< 1%). Serious injection site reactions were very rarely reported such as injection site infection, injection site abscess or injection site necrosis that could require surgical treatment/drainage. Tabulated list of adverse reactions The frequency of undesirable effects listed below is defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < /1 000) and very rare (< 1/10 000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Table 2: Frequency of adverse drug reactions reported in 1,259 patients treated for a total of 1,781 patient years (phase II and III studies) and from post-marketing reports MedDRA Very Common Uncommon Rare System Organ common Class (SOC) Blood and Anaemia* Neutropenic fever lymphatic system disorders Immune system Hypersensitivity Anaphylactic disorders reactions 5  MedDRA Very Common Uncommon Rare System Organ common Class

Auszug; vollständigen Abschnitt im Original lesen.

HOS-100437 · has-contraindication-information · PDF-Seite 3

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

HOS-100436 · has-indication-information · PDF-Seite 2

Degarelix Accord is a gonadotrophin releasing hormone (GnRH) antagonist indicated: - for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer

HOS-100439 · has-interaction-information · PDF-Seite 4

No interaction studies have been performed. Since androgen deprivation treatment may prolong the QTc interval, the concomitant use of degarelix with medicinal products known to prolong the QTc interval or medicinal products able to induce torsades de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be carefully evaluated (see section 4.4). Degarelix is not a substrate for the human CYP450 system and has not been shown to induce or inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4/5 to any great extent in vitro. Therefore, clinically significant pharmacokinetic drug-drug interactions in metabolism related to these isoenzymes are unlikely. 4

HOS-100440 · has-pregnancy-information · PDF-Seite 5

Pregnancy and breast-feeding There is no relevant indication for use of degarelix in women. Fertility Degarelix may inhibit male fertility as long as the testosterone is suppressed.

HOS-100438 · has-warning-information · PDF-Seite 3

Effect on QT/QTc interval Long-term androgen deprivation therapy may prolong the QT interval. In the confirmatory study comparing degarelix to leuprorelin periodic (monthly) electrocardiograms (ECGs) were performed; both therapies showed QT/QTc intervals exceeding 450 msec in approximately 20% of the patients, and 500 msec in 1% and 2% of the degarelix and leuprorelin patients, respectively (see section 5.1). Degarelix has not been studied in patients with a history of a corrected QT interval over 450 msec, in patients with a history of or risk factors for torsades de pointes and in patients receiving concomitant medicinal products that might prolong the QT interval. Therefore in such patients, the benefit/risk ratio of degarelix must be thoroughly appraised (see sections 4.5 and 4.8). A thorough QT study showed that there was no intrinsic effect of degarelix on QT/QTc interval (see section 4.8). 3 Hepatic impairment Patients with known or suspected hepatic disorder have not been included in long-term clinical trials with degarelix. Mild, transient increases in ALT and AST have been seen, these were not accompanied by a rise in bilirubin or clinical symptoms. Monitoring of liver function in patients with known or suspected hepatic disorder is advised during treatment. The pharmacokinetics of degarelix has been investigated after single intravenous administration in subjects with mild to moderate hepatic impairment (see section 5.2). Renal impairment Degarelix has not been studied in patients with severe renal impairment and caution is therefore warranted. Hypersensitivity Degarelix has not been studied in patients with a history of severe untreated asthma, anaphylactic reactions or severe urticaria or angioedema. Changes in bone density Decreased bone density has been reported in the medical literature in men who have had orchiectomy or who have been treated with a GnRH agonist. It can be anticipated that long periods of testosterone suppression in men will have effects on bone density. Bone density has not been measured during treatment with degarelix. Glucose tolerance A reduction in glucose tolerance has been observed in men who have had orchiectomy or who have been treated with a GnRH agonist. Development or aggravation of diabetes may occur; therefore diabetic patients may require more frequent monitoring of blood glucose when receiving androgen deprivation therapy. The effect of degare

Auszug; vollständigen Abschnitt im Original lesen.